<DOC>
	<DOCNO>NCT00797225</DOCNO>
	<brief_summary>This study design evaluate safety beneficial effect NBI-56418 compare placebo leuprorelin ( approved endometriosis therapy ) three month period follow additional three month treatment NBI-56418 .</brief_summary>
	<brief_title>Efficacy Safety Study Endometriosis With NBI-56418 ; Placebo Active Controlled</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Inclusion Criteria Be female , age 18 45 year , inclusive Have moderate severe pelvic pain due endometriosis Have surgically ( laparoscopy ) diagnose endometriosis within last 5 year recurrent persistent endometriosis symptom Have regular menstrual cycle ( 2333 day ) Agree use two form nonhormonal contraception study Exclusion Criteria Received Gonadotropinreleasing hormone ( GnRH ) agonist , GnRH antagonist , danazol , receive agent within 6 month start screen . Received subcutaneous medroxyprogesterone acetate ( DMPASC ) i.m . medroxyprogesterone acetate ( DMPAIM ) , receive either agent within 3 month start screen . Are currently use hormonal contraception form hormonal therapy receive treatment within last month Have surgery endometriosis within last month Are use systemic steroid chronic regular basis within 3 month Have uterine fibroid pelvic lesion â‰¥3 cm diameter Have hysterectomy oophorectomy Have pelvic pain cause endometriosis Have unstable medical condition chronic disease Have pregnant within last 6 month currently breast feed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>Endometriosis</keyword>
	<keyword>Pelvic Pain</keyword>
</DOC>